Clinical Trial

Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of GS-9716 as Monotherapy and in Combination With Anticancer Therapies in Adults With Solid Malignancies

Terminated Phase 1
View on ClinicalTrials.gov →
Why the trial stopped
Sponsor decision to terminate
Summary
This is a Phase I open-label, multi-center study of zamzetoclax (formerly GS-9716) tested either as monotherapy or in combination with other anti-cancer agents in patients with advanced solid malignancies. Primary objectives are to define the maximum tolerated dose (MTD) or maximum administered dose of zamzetoclax, and characterize the safety and tolerability of zamzetoclax as monotherapy and in combination with anti-cancer therapies.
Protocol Amendment History 5 changes
critical Trial terminated 2026-07-19
critical Reason stopped changed: — → Sponsor decision to terminate 2026-07-19
notable Enrollment reduced: 145 -> 37 participants 2026-07-19
notable Primary completion moved earlier: 2029-03 -> 2025-06-16 2026-07-19
minor Completion moved earlier: 2029-03 -> 2025-06-16 2026-07-19
Trial Details
NCT Number NCT05006794
Lead Sponsor Gilead Sciences
Conditions Solid Malignancies
Enrollment 37 participants
Start Date 2021-09-15
Primary Completion 2025-06-16 (estimated)
Study Completion 2025-06-16 (estimated)
Updated on ClinicalTrials.gov 2026-07-17